



Epidemiology

A cross-sectional study of the relationship between infant Thimerosal-containing hepatitis B vaccine exposure and attention-deficit/hyperactivity disorder

David A. Geier <sup>a, b</sup> ⊠, Janet K. Kern <sup>a, b, c</sup>  $\stackrel{\diamond}{\sim}$  ⊠, Kristin G. Homme <sup>d</sup> ⊠, Mark R. Geier <sup>a</sup> ⊠

- <sup>a</sup> Institute of Chronic Illnesses, Inc, Silver Spring, MD, USA
- <sup>b</sup> CoMeD, Inc., Silver Spring, MD, USA
- <sup>c</sup> CONEM US Autism Research Group, Allen, TX, USA
- <sup>d</sup> International Academy of Oral Medicine and Toxicology, ChampionsGate, FL, USA

Received 25 August 2017, Revised 25 October 2017, Accepted 5 November 2017, Available online 8 November 2017.



## Show less 🔨



to view subscribed content from home

\Xi Outline 🔀 Get Access Share Export


that is inconsistent with developmental level and interferes with normal functioning in at least two settings. This study evaluated the hypothesis that infant Thimerosal-containing hepatitis B vaccine (T-HepB) exposure would increase the risk of an ADHD diagnosis. This cross-sectional study examined 4393 persons between 13 and 19 years of age from the combined 1999–2004 National Health and Nutritional Examination Survey (NHANES) by analyzing demographic, immunization, socioeconomic, and healthrelated variables using the SAS system. Three doses of T-HepB exposure in comparison to no exposure significantly increased the risk of an ADHD diagnosis using logistic regression (adjusted odds ratio = 1.980), linear regression (adjusted betacoefficient = 0.04747), Spearman's rank (Rho = 0.04807), and  $2 \times 2$  contingency table (rate ratio = 1.8353) statistical modeling even when considering other covariates such as gender, race, and socioeconomic status. Current health status outcomes selected on an *a* priori basis to not be biologically plausibly linked to T-HepB exposure showed no relationship with T-HepB. The observed study results are biologically plausible and supported by numerous previous epidemiological studies, but because the NHANES data is collected on a cross-sectional basis, it is not possible to ascribe a direct cause-effect relationship between exposure to T-HepB and an ADHD diagnosis. During the decade from 1991 to 2001 that infants were routinely exposed to T-HepB in the United States (US), an estimated 1.3-2.5 million children were diagnosed with ADHD with excess lifetime costs estimated at US \$350-\$660 billion as a consequence of T-HepB. Although Thimerosal use in the HepB in the US has been discontinued, Thimerosal remains in the HepB in developing countries. Routine vaccination is an important public health tool to prevent infectious diseases, but every effort should be made to eliminate Thimerosal exposure.



Next

## Keywords

ADD; Attention deficit disorder; Ethylmercury; Mercury; Merthiolate; NHANES; Thiomersal





About ScienceDirect

Remote access

Shopping cart

Advertise

Contact and support

Terms and conditions

Privacy policy

We use cookies to help provide and enhance our service and tailor content and ads. By continuing you agree to the **use of cookies**. Copyright © 2020 Elsevier B.V. or its licensors or contributors. ScienceDirect ® is a registered trademark of Elsevier B.V. ScienceDirect ® is a registered trademark of Elsevier B.V.

